Executives seek “skin in the game” despite signs of a stock market cooldown.
Written by Nikkei Asia
Published on
7 May 2026
3 mins read
Global pharmaceutical executives are hungry for more deals with Chinese biotechnology companies after a record year, even as a stock market boom shows signs of cooling down.
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.
Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing…
Surging cross-border deals out of China are running headlong into intensifying US national security fears.
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs,…
